Infigratinib: all 30 studies that test it
Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.
- Open-Label, Long-Term, Extension Study of Infigratinib in Children With HypochondroplasiaEnrolling by invitationNCT07393373Phase 2
- An Interventional Study of Infigratinib in Children With HypochondroplasiaEnrolling by invitationNCT06873035Phase 2/3
- Extension Study of Infigratinib in Children With Achondroplasia (ACH)Enrolling by invitationNCT05145010Phase 2
- Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast CancerTerminatedNCT04504331Phase 1Results posted
- Infigratinib in Recurrent High-Grade Glioma PatientsTerminatedNCT04424966Early Phase 1Results posted
- Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene MutationsCompletedNCT04233567Phase 2Results posted
- Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial CancerTerminatedNCT04228042Phase 1/2Results posted
- Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic AlterationsTerminatedNCT04197986Phase 3Results posted
- Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/TranslocationsTerminatedNCT03773302Phase 3Results posted
- BGJ398 for the Treatment of Tumor-Induced OsteomalaciaTerminatedNCT03510455Phase 2Results posted
- BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck CancerTerminatedNCT02706691Phase 2Results posted
- BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the BladderCompletedNCT02657486Not applicableResults posted
- BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)CompletedNCT02257541Phase 1/2Results posted
- BGJ398 for Patients With Tumors With FGFR Genetic AlterationsTerminatedNCT02160041Phase 2Results posted
- LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF MelanomaCompletedNCT02159066Phase 2Results posted
- A Phase II, Single Arm Study of BGJ398 in Patients With Advanced CholangiocarcinomaTerminatedNCT02150967Phase 2Results posted
- A Phase 2 Study of BGJ398 in Patients With Recurrent GBMCompletedNCT01975701Phase 2Results posted
- Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaTerminatedNCT06206278Phase 2
- A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With AchondroplasiaCompletedNCT06164951Phase 3
- Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC TrialWithdrawnNCT05514912Phase 2
- Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/AmplificationWithdrawnNCT05510427Phase 1
- Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 AlterationsWithdrawnNCT05222165Phase 1/2
- Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR AlterationsStatus unknownNCT05019794Phase 2
- Phase I BLASST-3 TrialWithdrawnNCT04972253Phase 1
- Study of Infigratinib in Children With AchondroplasiaCompletedNCT04265651Phase 2
- Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic CancerWithdrawnNCT02575508Phase 1/2
- Ph Ib/BGJ398/Cervix and Other Solid TumorsWithdrawnNCT02312804Phase 1
- Phase 1b Trial of BGJ398/BYL719 in Solid TumorsCompletedNCT01928459Phase 1
- A Phase I Study of Oral BGJ398 in Asian PatientsCompletedNCT01697605Phase 1
- A Dose Escalation Study in Adult Patients With Advanced Solid MalignanciesCompletedNCT01004224Phase 1